Dexcom (DXCM) Net Income towards Common Stockholders (2010 - 2026)

Dexcom (DXCM) has reported Net Income towards Common Stockholders for 17 consecutive years, with $249.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 38.54% year-over-year to $249.1 million; the TTM figure through Jun 2026 stood at $999.7 million (up 74.93% YoY), while the FY2025 annual figure was $836.3 million, up 45.14% from the prior year.
• Net Income towards Common Stockholders climbed to $249.1 million in Q2 2026 per DXCM's latest filing, from $199.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $283.8 million in Q3 2025 and bottomed at $48.6 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged $152.4 million across 5 years, with a median of $139.0 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 1832.08% — and 2023, when it slumped 50.05%.
• Dexcom's Net Income towards Common Stockholders stood at $91.8 million in 2022, then soared by 179.19% to $256.3 million in 2023, then tumbled by 40.81% to $151.7 million in 2024, then surged by 76.2% to $267.3 million in 2025, then retreated by 6.81% to $249.1 million in 2026.
• Business Quant data shows DXCM's Net Income towards Common Stockholders at $249.1 million in Q2 2026, $199.5 million in Q1 2026, and $267.3 million in Q4 2025.